2026-06-14T02:29:24Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/160502025-04-30T12:41:24Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16988

00925njm 22002777a 4500 dc Rodríguez-Mora, Sara author Pérez-Lamas, Lucía author Sainero, Miriam Solera author Torres, Montserrat author Sánchez-Menéndez, Clara author Corona, Magdalena author Mateos, Elena author Casado-Fernández, Guiomar author Alcamí, José author García-Pérez, Javier author Perez-Olmeda, Mayte author Murciano-Antón, María Aranzazu author López-Jiménez, Javier author García-Gutiérrez, Valentín author Coiras, Mayte author 2023-02 The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (n = 11) or autologous (n = 18) HSCT. All participants had low but protective levels of neutralizing IgGs against SARS-CoV-2 after HSCT despite B-cell lymphopenia and immaturity. Although antibody-dependent cellular cytotoxicity was impaired, direct cellular cytotoxicity was similar to healthy donors in participants with autologous-HSCT, in contrast to individuals with allogeneic–HSCT, which severely deteriorated. No significant changes were observed in the immune response before and after HSCT. During follow-up, all reported post-HSCT SARS-CoV-2 infections were mild. This data emphasizes that COVID-19 vaccination is effective, necessary, and safe for individuals with OHD and also supports the persistence of some degree of immune protection after HSCT, at least in the short term, when patients cannot yet be revaccinated. Cancers. 2023,15:2344. 10.3390/cancers15082344 2072-6694 Cancers http://hdl.handle.net/20.500.12105/16050 COVID-19 vaccine Autologous transplantation Allogeneic transplantation Cytotoxic response Humoral response Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination